Den europeiske union - engelsk - EMA (European Medicines Agency)

sanofi pasteur europe - influenza virus (inactivated, split) of the following strains:a/california/7/2009 (h1n1)pdm09 - like strain (a/california/7/2009, nymc x-179a)a/hong kong/4801/2014 (h3n2) - like strain (a/hong kong/4801/2014, nymc x-263b)b/brisbane/60/2008 - like strain (b/brisbane/60/2008, wild type) - influenza, human; immunization - vaccines - prophylaxis of influenza in individuals 60 years of age and over, especially in those who run an increased risk of associated complications.the use of intanza should be based on official recommendations.

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi pasteur msd ltd - influenza virus split virion - suspension for injection

Irland - engelsk - HPRA (Health Products Regulatory Authority)

sanofi pasteur - rabies virus (inactivated) strain wistar (pm/wi 38-1503-3m) - powder and solvent for suspension for injection in pre-filled syringe - rabies, inactivated, whole virus

Irland - engelsk - HPRA (Health Products Regulatory Authority)

sanofi pasteur - hepatitis a virus - suspension for injection in pre-filled syringe - 160 d-ant. percent volume/volume - hepatitis vaccines; hepatitis a, inactivated, whole virus

Irland - engelsk - HPRA (Health Products Regulatory Authority)

sanofi pasteur - salmonella typhi, vi antigen - solution for injection - 25/0.5 microgram(s) - typhoid, purified polysaccharide antigen

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi pasteur - rabies virus inactivated - powder and solvent for suspension for injection

Irland - engelsk - HPRA (Health Products Regulatory Authority)

sanofi pasteur msd ltd - pneumococcal polysaccharide serotype 1, pneumococcal polysaccharide type 2 (2), pneumococcal polysaccharide type 3 (3), pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 5, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 7f, pneumococcal polysaccharide type 8 (8), pneumococcal polysaccharide type 9n, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide type 20 (20), pneumococcal oligosaccharide serotype 18c, pneumococcal polysaccharide - solution for injection in pre-filled syringe - 25/0.5 microgram/ml - pneumococcal vaccines - it is recommended for active immunisation against disease caused by the pneumococcal serotypes included in the vaccine

Malta - engelsk - Medicines Authority

sanofi pasteur 14 espace henry vallée , 69007 lyon, france - pertactin, pertussis toxoid, diphtheria toxoid, filamentous haemagglutinin, fha, fimbriae types, and, tetanus toxoid - suspension for injection - pertactin 3 µg pertussis toxoid 2.5 µg diphtheria toxoid filamentous haemagglutinin (fha) 5 µg fimbriae types 2 and 3 5 µg tetanus toxoid - vaccines

Malta - engelsk - Medicines Authority

sanofi pasteur 14 espace henry vallée , 69007 lyon, france - tetanus toxoid - suspension for injection - tetanus toxoid 40 iu - vaccines

USA - engelsk - NLM (National Library of Medicine)

sanofi pasteur inc. - influenza a virus a/california/7/2009(h1n1)-like antigen (formaldehyde inactivated) (unii: 5i5hvc73i8) (influenza a virus a/california/7/2009(h1n1)-like hemagglutinin antigen (formaldehyde inactivated) - unii:euj84un96z) - influenza a virus a/california/7/2009(h1n1)-like hemagglutinin antigen (formaldehyde inactivated) 15 ug in 0.5 ml - influenza a (h1n1) 2009 monovalent vaccine is an inactivated influenza virus vaccine indicated for active immunization of persons 6 months of age and older against influenza disease caused by pandemic (h1n1) 2009 virus. do not administer influenza a (h1n1) 2009 monovalent vaccine to anyone with a known severe hypersensitivity to egg proteins or any component of the vaccine or life-threatening reactions after previous administration of any influenza vaccine. [see warnings and precautions (5) and description (11) ] sanofi pasteur's influenza a (h1n1) 2009 monovalent vaccine and seasonal trivalent influenza virus vaccine (fluzone vaccine) are manufactured by the same process. available information for fluzone vaccine is provided in this section. pregnancy category c: animal reproduction studies have not been conducted with influenza a (h1n1) 2009 monovalent vaccine or fluzone vaccine. it is also not known whether these vaccines can cause fetal harm when administered to a pregnant woman or can affect reproduction